Amunix

Amunix is a company in the field of immuno-oncology utilizing its exclusive, clinically verified Pro-XTEN technology platform to explore and create revolutionary T cell engagers (TCEs) and cytokine therapies for individuals dealing with cancer. The objective is to broaden the therapeutic range of TCEs and cytokines, which have shown clinical anti-tumor effectiveness but have not fully realized their potential due to dose-related toxicity on-target and off-tumor. This challenge is tackled by employing the universal, protease-releasable masking technology (Pro-XTEN) to produce conditionally active TCEs (XPATs®) and cytokines (XPACs).